张之昊 博士 高聘研究员 博(硕)士生导师
电子邮箱:zzhao@hainanu.edu.cn;zzh-198518@163.com
1.教育背景
2003.9-2007.7 中国药科大学,药物制剂,理学学士
2007.9-2010.7 中国药科大学,药物化学,理学硕士
2010.9-2013.8 澳门科技大学,中药药理学,理学博士
2014.1-2015.7 密西西北大学,博士后研究
2015.9-2017.6 美国橡树岭国家实验室,博士后研究
2.科研情况
课题组围绕抗慢性肾病活性物质作用机制展开系列工作,探索抗肾纤维化新靶点、新机制,近年来在Nature Communications、Cell reports、Pharmacological Research、npj Biofilms and Microbiomes、Theranostics、Phytomedicine和Acta Pharmacol Sin等国际知名杂志发表SCI收载论文41余篇,其中第一/通讯作者论文36篇,他引次数累计2500多次。主持承担国家自然科学基金2项、海南省自然基金1项,作为重要成员参与科技部重大新药创制1项、教育部校双一流建设项目1项,横向项目3项。已授权发明专利4项。
3.研究领域
肾脏药理学、代谢组学和肠道菌群
4.代表性项目
1) 国家自然科学基金地区基金“卵形拟杆菌抑制铁死亡治疗慢性肾脏病的机制研究” (主持)
2) 国自然青年基金“基于TGF-β/Smad通路和脂质代谢探讨大黄抗肾纤维化的药效物质基础及作用机制”(主持)
3) 海南省自然科学基金面上项目“大黄活性成分在慢性肾脏病治疗中的作用及机制研究” (主持)
4) 苏黄止咳胶囊关键药效成分质量标准的建立、药效成分群的机理及药材溯源系统研究(扬子江横向项目,主持)
5) 苏黄止咳胶囊的体内代谢、关键药效成分单体及其组合的止咳药效作用考察及作用机制(扬子江横向项目,主持)
6) 基于代谢组学的结直肠息肉代谢标志物预警及中药干预研究(无锡江阴中医院横向项目10万,主持)
7) 校双一流高峰课题“中药天然药物来源环肽类与多酚类肿瘤干预创新药的研发”(主持)
5.代表性成果
1) Wei Zhou, Wen-hui Wu, Zi-lin Si, ….. , Ning-hua Tan*, Zhi-hao Zhang*, The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice, Nature communications, 2022, 13, 6081. (IF = 17.694, 1区)
2) Zi-lin Si, Han-yu Wang, Tao Wang, ….. , Jun-hui Li, Jing Li*, Hong-wei Liu*, Zhi-hao Zhang*. Gut Bacteroides ovatus ameliorates renal fibrosis by promoting the production of HDCA through upregulation of Clostridium scindens. Cell reports, 2024, 43(10), 114830. (IF = 8.8, 1区)
3) Yi-Zhi Cao #, Jiang-Yi Li #, Jun-Ming Hu#, Ke Su, Jia-Liang Chen, Ying Liu*, Jia-Li Wei*, Zhi-Hao Zhang*. Clostridium scindens attenuates acute kidney injury by producing indole-3-acetic acid. npj Biofilms and Microbiomes, 2025, 12(1), 16. (IF = 11.4, 1区)
4) Hong Zhang†, Lu Zheng†, Ting Tang†, ….. ,Jun Jing*, Li Chen*, Zhihao Zhang*, Bing Yao. Omega-3 Fatty Acids alleviate ovarian aging through Gut Microbiota-Epithelial Crosstalk, SCIENCE CHINA Life Sciences, 2026, Accept. (IF = 9.6, 1区)
5) Hui-ling Liu, Zhou Huang, Qing-zhen Li, Yi-zhi Cao, Han-yu Wang, Raphael N. Alolgab, Xue-yang Deng, Zhi-hao Zhang*. Schisandrin A alleviates renal fibrosis by inhibiting PKCβ and oxidative stress. Phytomedicine, 2024, 126,155372. (IF = 11.3, 1区)
6) Wei Zhou†, Min-min Chen†, Hui-ling Liu†, …. , Ning-hua Tan* and Zhi-hao Zhang*, Dihydroartemisinin suppresses renal fibrosis in mice by nhibiting DNA-methyltransferase 1 and increasing Klotho, Acta Pharmacol Sin, 2022, 0, 1–15. (IF = 10.4, 1区)
7) Ke Su, Bo Yi*, … Yi-fei Yang, Zhi-hao Zhang*, Cheng Chen*, Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis, Pharmacological Research, 2020, 156, 104778. (IF = 12.2, 1区)
8) Zhihao Zhang†, Jun-Qiu He†, Ying-Yong, Zhao, Huachao Chen*, Ninghua Tan*. Asiatic acid prevents renal fibrosis in UUO rats via promoting the production of 15d-PGJ2, an endogenous ligand of PPAR-γ. Acta Pharmacol Sin, 2020, 41, 373–382. (IF = 10.4, 1区)
9) Huachao Chen†, Fei Li†, …. , Zhihao Zhang*, Ninghua Tan*. Redox Dual-Responsive and O2‑Evolving Theranostic Nanosystem for Highly Selective Chemotherapy against Hypoxic Tumor, Theranostics, 2019, 9 (1), 90-103. (IF = 14.9, 1区)
10) Zhihao Zhang, Zulfiqar Ali, Shabana I Khan, Ikhlas A. Khan*. Cytotoxic monacolins from red yeast rice, a Chinese medicine and food, Food Chemistry, 2016, 202, 262–268. (IF = 10.4, 1区)
11) Hao Liang, Yun-Xing Ji, Rui-Han Wang, Zhi-Hao Zhang*, and Bo Zhang*. Visible-Light-Initiated Manganese-Catalyzed E-Selective Hydrosilylation and Hydrogermylation of Alkynes, Organic Letters, 2019, 21(8), 2750-2754. (SCI, IF = 6.072, 1区)
6.荣誉奖励
2023年4月以海南省高层次人才引进进入海南大学药学院。
2025年海南省“四方之才”汇聚计划优秀人才团队核心成员
课题组长期招聘分子生物学、药理学、代谢组学和肠道微生物背景的研究生、博士和博士后加盟!